United States Patent 9,125,889: Ibrutinib Patent Scope, Claims, Expiration and Competitive Landscape
U.S. Patent No. 9,125,889 protects a dosing method for treating previously treated Waldenström's macroglobulinemia with an oral Bruton's tyrosine kinase inhibitor, specifically ibrutinib. The commercially relevant embodiment is ibrutinib at 420 mg once daily. The patent issued to Pharmacyclics LLC and is associated with Imbruvica, marketed by Pharmacyclics and Janssen Biotech.
The patent is a method-of-use patent. It does not broadly protect the ibrutinib molecule, all BTK inhibitors, or every use of ibrutinib. Its enforceable scope depends on satisfying each required element: Waldenström's macroglobulinemia, at least one prior therapy, oral administration, once-daily dosing, and the claimed 420 mg-to-840 mg dose range.
What does U.S. Patent 9,125,889 protect?
The patent protects treatment of Waldenström's macroglobulinemia in an individual who has already received at least one prior therapy by administering a once-daily oral dose of a BTK inhibitor having the claimed chemical structure.
The claimed structure is ibrutinib, also known as PCI-32765. The principal claim elements are:
| Claim element |
Requirement |
| Disease |
Waldenström's macroglobulinemia |
| Patient status |
The patient previously received at least one WM therapy |
| Active agent |
A BTK inhibitor having the claimed ibrutinib structure |
| Route |
Oral |
| Frequency |
Once per day |
| Dose |
About 420 mg to about 840 mg |
| Dependent claim 2 |
About 420 mg once daily |
Claim 1 is a combination of a disease-specific indication and a dosing regimen. Claim 2 narrows the regimen to approximately 420 mg once daily, the dose used in the FDA-approved Imbruvica regimen for WM.
What is the scope of claim 1?
Claim 1 covers a method only when all limitations are met. A potential infringing use would generally require:
- Treatment of a patient with WM.
- A patient who has already received at least one prior WM therapy.
- Oral administration.
- Administration once per day.
- A daily dose within the approximately 420 mg-to-840 mg range.
- Use of the claimed ibrutinib structure.
The claim does not require a particular prior therapy. The prior treatment could be chemotherapy, immunotherapy, a targeted therapy, or another recognized WM treatment, provided the patient has received at least one prior therapy.
The claim also does not expressly require a particular response, such as partial response, major response, progression-free survival, or reduction in IgM. Treatment intent and administration of the claimed regimen are the central limitations.
What is the scope of claim 2?
Claim 2 covers the narrower 420 mg once-daily regimen. It is commercially important because 420 mg once daily is the standard WM dose reflected in the Imbruvica labeling.
A generic or competing product that uses 420 mg once daily for previously treated WM would face a direct method-of-use issue if the relevant patent remains enforceable and the product labeling encourages that use. A product labeled only for a non-WM indication, or with WM use carved out, would present a different infringement analysis.
Which drug does Patent 9,125,889 cover?
The patent covers ibrutinib, the active ingredient in Imbruvica. Ibrutinib forms a covalent bond with BTK at cysteine 481 and inhibits BTK signaling involved in B-cell receptor pathways.
Imbruvica is marketed by Pharmacyclics LLC, an AbbVie company, and Janssen Biotech, a Johnson & Johnson company. The FDA approved ibrutinib for WM on January 28, 2015, after accelerated-approval development based on response data in patients with previously treated disease.[2]
The original WM approval aligned closely with the patent claims because it addressed patients with prior therapy and used a 420 mg once-daily oral dose. The FDA label later broadened the clinical positioning of ibrutinib in WM beyond the original previously treated population.[2]
When does U.S. Patent 9,125,889 expire?
The patent has a 20-year patent term measured from the applicable nonprovisional filing date, subject to patent-term adjustment and any terminal disclaimer. Public patent databases generally identify a March 2031 expiration period for the relevant U.S. family.[1]
| Event |
Date or status |
| U.S. patent application family |
Filed in the 2011 period |
| Patent issued |
September 8, 2015 |
| Patent number |
US 9,125,889 |
| Expected base-term period |
March 2031 |
| Patent type |
Method of treatment and dosing |
| Patent-term adjustment |
Must be confirmed from the USPTO patent record |
| Post-expiration status |
Claims no longer enforceable, absent an unusual statutory extension |
The patent is distinct from earlier and later ibrutinib patents covering the compound, crystalline forms, formulations, manufacturing processes, combinations, and other indications. A generic launch analysis cannot rely on the expiration of Patent 9,125,889 alone.
What is the Orange Book status of Patent 9,125,889?
The FDA Orange Book is the relevant source for determining whether a patent is listed against an approved small-molecule drug and whether the listing carries a use code.[3]
For Imbruvica, the Orange Book patent estate has included patents directed to the active ingredient, drug product, methods of use, and specific indications. Patent 9,125,889 is the type of patent that can be listed as a method-of-use patent because it covers treatment of a particular disease with a specified regimen.
An Orange Book listing can affect an ANDA applicant in two ways:
- A Paragraph IV certification may challenge the patent as invalid, unenforceable, or not infringed.
- A section viii statement may attempt to omit the patented indication from the generic label.
For a 420 mg ibrutinib product, the commercial risk depends on whether the proposed label includes WM treatment and whether the patented use can be carved out without creating a legally or commercially incomplete label. The Orange Book listing and current use code control the practical analysis.[3]
What FDA exclusivity protected ibrutinib in Waldenström's macroglobulinemia?
FDA regulatory exclusivity and patent protection are separate rights.
| Protection |
Relevance to ibrutinib WM |
| Orphan-drug exclusivity |
Potential seven-year exclusivity from the WM approval date, subject to scope and statutory exceptions |
| New chemical entity exclusivity |
Applied to the original active ingredient approval, not indefinitely to later indications |
| Patent protection |
May extend beyond regulatory exclusivity and cover specific use, formulation, or compound claims |
| Pediatric exclusivity |
Can add six months if granted for qualifying pediatric studies |
| ANDA approval |
May be blocked or delayed by patents and statutory exclusivity |
The WM approval was granted in 2015. Any seven-year orphan exclusivity associated with that approval would not replace the longer patent protection and would generally have expired in the early 2020s. Patent 9,125,889 therefore has greater relevance to late-decade generic-entry analysis than the original WM regulatory exclusivity.
How strong is the patent estate for ibrutinib?
The ibrutinib estate is stronger than Patent 9,125,889 considered in isolation because multiple patent categories may affect a competing product.
Core patent categories
| Patent category |
Commercial protection |
| Compound patents |
Protect ibrutinib and related chemical matter |
| Salt and crystal-form patents |
Protect selected solid-state forms |
| Formulation patents |
Protect dosage forms, excipients, release characteristics, or drug products |
| Method-of-use patents |
Protect CLL, WM, MCL, MZL and other treatment regimens |
| Combination patents |
Protect combinations with anti-CD20 antibodies or other agents |
| Manufacturing patents |
Protect synthesis, intermediates, purification, and process conditions |
Patent 9,125,889 is commercially meaningful because the 420 mg WM dose is the labeled and clinically established regimen. It is less comprehensive than a compound patent. If the compound and product patents expire earlier or are successfully challenged, a generic applicant may still face the use patent for a labeled WM indication.
What formulations are protected by the broader estate?
Ibrutinib has been marketed in capsules and tablets. Separate patents may address tablet formulations, dosage strengths, excipients, manufacturing processes, and pharmaceutical compositions. A generic applicant can sometimes avoid formulation claims by using a different excipient system or dosage-form process. It cannot assume that a formulation design-around eliminates method-of-use exposure.
Which companies are challenging the ibrutinib patent estate?
Generic ibrutinib development has involved major ANDA manufacturers, including companies such as Teva, Cipla, Lupin, Hetero, Natco, Dr. Reddy's Laboratories, and Zydus in various filings and patent disputes involving the broader Imbruvica estate.
The relevant litigation questions are:
- Was a Paragraph IV certification filed?
- Which Orange Book patents were challenged?
- Did the NDA holder sue within 45 days?
- Was a 30-month stay triggered?
- Did the parties settle?
- Does the settlement permit an agreed launch date?
- Does the generic label carve out WM or another patented indication?
Public litigation involving ibrutinib has generally focused on the broader patent portfolio rather than treating Patent 9,125,889 as the only barrier. Patent-specific conclusions require review of the applicable complaint, ANDA notice letter, settlement, and Orange Book entry. No final invalidity judgment should be inferred merely from the existence of a Paragraph IV challenge.
What patent litigation affects ibrutinib generic entry?
Ibrutinib litigation can involve:
- Compound patents covering ibrutinib.
- Method patents covering hematologic malignancies.
- Formulation patents covering tablets or capsules.
- Manufacturing patents covering intermediates and synthetic routes.
- Patent-term and terminal-disclaimer disputes.
- Inducement claims based on generic labeling.
- Skinny-label disputes involving WM or other indications.
For Patent 9,125,889, the central litigation issues would likely include claim construction for “about,” the meaning of “once per day,” whether the patient had received a prior WM therapy, and whether the accused product label induces the claimed use.
A generic product could reduce exposure through a section viii carve-out if FDA labeling rules permit removal of the patented WM indication. That strategy is less effective if the remaining label, promotional materials, dosing instructions, or distribution practices encourage the patented use.
What generic launch scenarios exist for ibrutinib?
Scenario 1: Launch after all relevant patents expire
This is the lowest litigation-risk scenario. A generic could market ibrutinib for approved indications after the last blocking compound, formulation, and method patents expire.
Scenario 2: Skinny-label launch
A generic could seek approval for unpatented indications while omitting WM or another patented use. The commercial value depends on the remaining indication set and physician prescribing behavior.
Scenario 3: Paragraph IV launch after a successful challenge
A successful invalidity or noninfringement decision could permit earlier entry. The outcome would depend on the specific patent claims and the generic product's label.
Scenario 4: Settlement-based launch
A settlement could establish an agreed entry date before patent expiration. Such agreements may contain acceleration provisions if the patent estate is later invalidated or another generic enters.
Scenario 5: At-risk launch
A company could launch before final resolution, accepting possible damages and injunctive exposure. This strategy is less likely when several independent patents remain enforceable.
How does Patent 9,125,889 compare with competing BTK inhibitor patents?
| Drug |
Sponsor |
BTK profile |
WM relevance |
| Ibrutinib |
Pharmacyclics/Janssen |
Covalent BTK inhibitor |
FDA-approved WM treatment |
| Zanubrutinib |
BeiGene |
Covalent BTK inhibitor |
FDA-approved for WM |
| Acalabrutinib |
AstraZeneca |
Covalent BTK inhibitor |
Primarily CLL and MCL positioning |
| Pirtobrutinib |
Eli Lilly/previously Loxo |
Noncovalent BTK inhibitor |
Distinct chemical and patent estate |
Patent 9,125,889 does not cover zanubrutinib, acalabrutinib, or pirtobrutinib because its structural limitation is directed to ibrutinib. It also does not prevent use of another BTK inhibitor for WM. Its competitive effect is therefore specific to ibrutinib products and labels.
What manufacturing and geographic barriers remain?
Patent 9,125,889 is a U.S. method patent. It does not automatically establish equivalent rights in Europe, Japan, China, Canada, or other jurisdictions. Foreign counterparts must be analyzed separately for claim scope, prosecution history, term, validity, and national enforcement.
Manufacturing barriers may remain even after method claims weaken. A supplier may need to design around process patents, obtain access to protected intermediates, qualify an alternative crystalline form, and satisfy FDA chemistry, manufacturing, and controls requirements.
The U.S. patent landscape is therefore layered:
- Use claims affect the label and prescribing behavior.
- Product claims affect the drug substance and dosage form.
- Process claims affect manufacturing.
- Regulatory exclusivity affects approval timing.
- Litigation settlements affect actual launch timing.
Key Takeaways
- U.S. Patent 9,125,889 is a method-of-use patent for treating previously treated WM with oral ibrutinib.
- Claim 1 covers approximately 420 mg to 840 mg once daily.
- Claim 2 specifically covers approximately 420 mg once daily.
- The patent does not cover all BTK inhibitors or all ibrutinib uses.
- The patent is closely aligned with the original FDA-approved WM regimen for Imbruvica.
- The expected patent-term period extends into March 2031, subject to USPTO term calculations.
- Generic risk depends on the full Imbruvica patent estate, not this patent alone.
- Paragraph IV challenges, skinny-label strategies, and settlements are the main routes to earlier ibrutinib entry.
- Patent 9,125,889 is specific to ibrutinib and does not block competing BTK inhibitors such as zanubrutinib or pirtobrutinib.
FAQs About U.S. Patent 9,125,889
Does Patent 9,125,889 cover first-line treatment of Waldenström's macroglobulinemia?
No. The claims require an individual who has already received at least one prior WM therapy. First-line treatment is outside the express scope of that limitation.
Does the patent cover an ibrutinib dose below 420 mg?
Not expressly. Claim 1 requires a dose of about 420 mg to about 840 mg, and claim 2 requires about 420 mg. A materially lower dose would require a separate infringement analysis and would not fall within the ordinary literal scope of these claims.
Does Patent 9,125,889 cover intravenous BTK inhibitors?
No. The claims require an oral dose administered once per day. Intravenous administration does not meet the express route limitation.
Can a generic ibrutinib company omit the WM indication?
Potentially, if FDA labeling rules permit a section viii carve-out and the resulting label does not encourage the patented WM use. Other Orange Book patents and inducement theories may still affect launch risk.
Does Patent 9,125,889 block zanubrutinib for WM?
No. The patent claims the ibrutinib chemical structure. Zanubrutinib is a different BTK inhibitor and requires separate patent analysis.
References
- United States Patent and Trademark Office. (2015). U.S. Patent No. 9,125,889: Use of inhibitors of Bruton's tyrosine kinase (Btk). U.S. Department of Commerce.
- U.S. Food and Drug Administration. (2023). Imbruvica (ibrutinib) prescribing information.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.
- U.S. Food and Drug Administration. (2024). Drugs@FDA: Imbruvica application and approval history. U.S. Department of Health and Human Services.
